Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography

Application to pharmacokinetic study in relation to CYP2C19 genotypes

Mikiko Shimizu, Tsukasa Uno, Takenori Niioka, Norio Yaui-Furukori, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A simple and sensitive column-switching high-performance liquid chromatographic method was developed for the simultaneous determination of omeprazole and its two main metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in human plasma. Omeprazole, its two metabolites and lansoprazol as an internal standard were extracted from 1 ml of alkalinized plasma sample using diethyl ether-dichloromethane (45:55, v/v). The extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm i.d.) for clean-up and column II (Inertsil ODS-80A column, 5 μm, 150 mm × 4.6 mm i.d.) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (92:8 v/v, pH 7.0) for clean-up and phosphate buffer-acetonitrile-methanol (65:30:5 v/v/v, pH 6.5) for separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was ∼25 min. The validated concentration ranges of this method were 3-2000 ng/ml for omeprazole, 3-500 ng/ml for 5-hydroxyomeprazole and 3-1000 ng/ml for omeprazole sulfone. Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone. Intra- and inter-day coefficient variations were less than 5.1 and 6.6% for omeprazole, 4.6 and 5.0% for 5-hydroxyomeprazole and 4.6 and 4.9% for omeprazole sulfone at the different concentrations. The limits of quantification were 3 ng/ml for omeprazole and its metabolites. This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity.

Original languageEnglish
Pages (from-to)241-248
Number of pages8
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume832
Issue number2
DOIs
Publication statusPublished - 2006 Mar 7
Externally publishedYes

Fingerprint

Plasma (human)
Pharmacokinetics
Omeprazole
High performance liquid chromatography
Metabolites
Genotype
High Pressure Liquid Chromatography
Buffers
Phosphates
Ultraviolet detectors
Lansoprazole
Methylene Chloride
Ether
Methanol
Cytochrome P-450 CYP2C19
Volunteers
Plasmas
Recovery
Wavelength
5-hydroxymethylomeprazole

Keywords

  • 5-Hydroxyomeprazole
  • CYP2C19
  • HPLC
  • Omeprazole
  • Omeprazole sulfone

ASJC Scopus subject areas

  • Biochemistry

Cite this

Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography : Application to pharmacokinetic study in relation to CYP2C19 genotypes. / Shimizu, Mikiko; Uno, Tsukasa; Niioka, Takenori; Yaui-Furukori, Norio; Takahata, Takenori; Sugawara, Kazunobu; Tateishi, Tomonori.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 832, No. 2, 07.03.2006, p. 241-248.

Research output: Contribution to journalArticle

@article{8abd9957d1c74e258b604078ff93604d,
title = "Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: Application to pharmacokinetic study in relation to CYP2C19 genotypes",
abstract = "A simple and sensitive column-switching high-performance liquid chromatographic method was developed for the simultaneous determination of omeprazole and its two main metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in human plasma. Omeprazole, its two metabolites and lansoprazol as an internal standard were extracted from 1 ml of alkalinized plasma sample using diethyl ether-dichloromethane (45:55, v/v). The extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm i.d.) for clean-up and column II (Inertsil ODS-80A column, 5 μm, 150 mm × 4.6 mm i.d.) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (92:8 v/v, pH 7.0) for clean-up and phosphate buffer-acetonitrile-methanol (65:30:5 v/v/v, pH 6.5) for separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was ∼25 min. The validated concentration ranges of this method were 3-2000 ng/ml for omeprazole, 3-500 ng/ml for 5-hydroxyomeprazole and 3-1000 ng/ml for omeprazole sulfone. Mean recoveries were 84.3{\%} for omeprazole, 64.3{\%} for 5-hydroxyomeprazole and 86.1{\%} for omeprazole sulfone. Intra- and inter-day coefficient variations were less than 5.1 and 6.6{\%} for omeprazole, 4.6 and 5.0{\%} for 5-hydroxyomeprazole and 4.6 and 4.9{\%} for omeprazole sulfone at the different concentrations. The limits of quantification were 3 ng/ml for omeprazole and its metabolites. This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity.",
keywords = "5-Hydroxyomeprazole, CYP2C19, HPLC, Omeprazole, Omeprazole sulfone",
author = "Mikiko Shimizu and Tsukasa Uno and Takenori Niioka and Norio Yaui-Furukori and Takenori Takahata and Kazunobu Sugawara and Tomonori Tateishi",
year = "2006",
month = "3",
day = "7",
doi = "10.1016/j.jchromb.2006.01.022",
language = "English",
volume = "832",
pages = "241--248",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography

T2 - Application to pharmacokinetic study in relation to CYP2C19 genotypes

AU - Shimizu, Mikiko

AU - Uno, Tsukasa

AU - Niioka, Takenori

AU - Yaui-Furukori, Norio

AU - Takahata, Takenori

AU - Sugawara, Kazunobu

AU - Tateishi, Tomonori

PY - 2006/3/7

Y1 - 2006/3/7

N2 - A simple and sensitive column-switching high-performance liquid chromatographic method was developed for the simultaneous determination of omeprazole and its two main metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in human plasma. Omeprazole, its two metabolites and lansoprazol as an internal standard were extracted from 1 ml of alkalinized plasma sample using diethyl ether-dichloromethane (45:55, v/v). The extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm i.d.) for clean-up and column II (Inertsil ODS-80A column, 5 μm, 150 mm × 4.6 mm i.d.) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (92:8 v/v, pH 7.0) for clean-up and phosphate buffer-acetonitrile-methanol (65:30:5 v/v/v, pH 6.5) for separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was ∼25 min. The validated concentration ranges of this method were 3-2000 ng/ml for omeprazole, 3-500 ng/ml for 5-hydroxyomeprazole and 3-1000 ng/ml for omeprazole sulfone. Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone. Intra- and inter-day coefficient variations were less than 5.1 and 6.6% for omeprazole, 4.6 and 5.0% for 5-hydroxyomeprazole and 4.6 and 4.9% for omeprazole sulfone at the different concentrations. The limits of quantification were 3 ng/ml for omeprazole and its metabolites. This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity.

AB - A simple and sensitive column-switching high-performance liquid chromatographic method was developed for the simultaneous determination of omeprazole and its two main metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in human plasma. Omeprazole, its two metabolites and lansoprazol as an internal standard were extracted from 1 ml of alkalinized plasma sample using diethyl ether-dichloromethane (45:55, v/v). The extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm i.d.) for clean-up and column II (Inertsil ODS-80A column, 5 μm, 150 mm × 4.6 mm i.d.) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (92:8 v/v, pH 7.0) for clean-up and phosphate buffer-acetonitrile-methanol (65:30:5 v/v/v, pH 6.5) for separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 302 nm, and total time for chromatographic separation was ∼25 min. The validated concentration ranges of this method were 3-2000 ng/ml for omeprazole, 3-500 ng/ml for 5-hydroxyomeprazole and 3-1000 ng/ml for omeprazole sulfone. Mean recoveries were 84.3% for omeprazole, 64.3% for 5-hydroxyomeprazole and 86.1% for omeprazole sulfone. Intra- and inter-day coefficient variations were less than 5.1 and 6.6% for omeprazole, 4.6 and 5.0% for 5-hydroxyomeprazole and 4.6 and 4.9% for omeprazole sulfone at the different concentrations. The limits of quantification were 3 ng/ml for omeprazole and its metabolites. This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity.

KW - 5-Hydroxyomeprazole

KW - CYP2C19

KW - HPLC

KW - Omeprazole

KW - Omeprazole sulfone

UR - http://www.scopus.com/inward/record.url?scp=33644777564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644777564&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2006.01.022

DO - 10.1016/j.jchromb.2006.01.022

M3 - Article

VL - 832

SP - 241

EP - 248

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 2

ER -